The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review
Ioanna A. Paschou, Evangelia Sali, Stavroula Α. Paschou, Θεοδώρα Ψαλτοπούλου, Electra Nicolaidou, Alexander J. Stratigos
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP-1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction. It has also been established that GLP-1RA have immunological and anti-inflammatory effects. The aim of this article was to comprehensively review the literature and to collect, analyse and quantitatively resynthesize evidence on the possible effects of GLP-1RA on inflammatory skin diseases. Through body weight reduction and subsequent systemic inflammation reduction, but mainly through their direct interaction with signalling pathways of inflammation and immune cells, GLP-1RA can improve psoriasis and hidradenitis suppurativa (HS). Clinical data of the positive effects of GLP-1RA in patients with psoriasis and HS are presented. Moreover, the immune cells and inflammatory pathways affected by GLP-1RA are discussed.